AtriCure, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $534.5M | $465.3M | $399.2M | $330.4M | $274.3M | $206.5M | $230.8M | $201.6M |
| Cost of Revenue | $133.7M | $117.8M | $98.9M | $84.4M | $68.5M | $57.2M | $60.5M | $54.5M |
| Gross Profit | $400.8M | $347.5M | $300.4M | $245.9M | $205.9M | $149.3M | $170.3M | $147.1M |
| Gross Margin | 75.0% | 74.7% | 75.2% | 74.4% | 75.0% | 72.3% | 73.8% | 73.0% |
| Operating Expenses | ||||||||
| Research & Development | $99.2M | $96.2M | $73.9M | $57.3M | $48.5M | $43.1M | $41.2M | $34.7M |
| SG&A Expense | $311.0M | $291.4M | $253.1M | $231.3M | $204.6M | $150.8M | $167.1M | $129.5M |
| Operating Income | $-9.4M | $-40.0M | $-26.7M | $-42.7M | $55.2M | $-44.2M | $-33.1M | $-17.1M |
| Operating Margin | -1.8% | -8.6% | -6.7% | -12.9% | 20.1% | -21.4% | -14.4% | -8.5% |
| Interest Expense | — | — | $6.9M | $5.0M | $4.9M | $4.9M | $4.1M | $4.6M |
| Pretax Income | $-10.2M | $-43.7M | $-29.8M | $-46.2M | $50.4M | $-48.0M | $-35.0M | $-20.9M |
| Income Tax Expense | $1.3M | $1.0M | $591.0K | $268.0K | $188.0K | $114.0K | $199.0K | $226.0K |
| Net Income | $-11.4M | $-44.7M | $-30.4M | $-46.5M | $50.2M | $-48.2M | $-35.2M | $-21.1M |
| Net Margin | -2.1% | -9.6% | -7.6% | -14.1% | 18.3% | -23.3% | -15.2% | -10.5% |
| EPS (Basic) | $-0.24 | $-0.95 | $-0.66 | $-1.02 | $1.11 | $-1.14 | $-0.94 | $-0.62 |
| EPS (Diluted) | $-0.24 | $-0.95 | $-0.66 | $-1.02 | $1.09 | $-1.14 | $-0.94 | $-0.62 |
| Shares Outstanding (Basic) | 47.8M | 47.0M | 46.3M | 45.7M | 45.1M | 42.1M | 37.6M | 38.6M |
| Shares Outstanding (Diluted) | 47.8M | 47.0M | 46.3M | 45.7M | 46.0M | 42.1M | 37.6M | 38.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |